Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Método de detección del virus del papiloma humano

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOCZ20150701001
Publicado:
03/08/2015
Caducidad:
02/08/2016
Resumen:
Un centro de investigación checo ha desarrollado un método de detección del virus del papiloma humano (VPH). El cáncer cervical es el séptimo cáncer más frecuente, con una tasa de mortalidad de 6,8 por 100.000. La causa se atribuye a formas agresivas del virus del papiloma humano. El método de detección desarrollado se basa en reacción en cadena de la polimerasa y es sencillo, rápido y fiable. El centro de investigación busca un socio con capacidad de producción que ofrezca asistencia para continuar con la investigación y desarrollo y lanzar el producto a mercados globales. El objetivo es establecer acuerdos de joint venture, licencia o fabricación.

Details

Tittle:
Method for detection of human papilloma virus
Summary:
A large Czech research centre has developed a detection method of human papilloma virus (HPV). Cervical cancer ranks seventh among the most common malignancies with a mortality rate of 6.8 per 100 000. The cause has been attributed to aggressive forms of HPV. A partner with manufacturing ability, support for further related research and development and the ability to place the technology on global markets based on a joint-venture, licence or manufacturing agreement is sought.
Description:
Cervical cancer ranks seventh among the most common malignancies with a mortality rate of 6.8 per 100 000. The cause has been attributed to aggressive forms of HPV (human papilloma virus). More than 2.6 billion women are at risk of developing this cancer and about 500 000 cases are annually detected worldwide. The technology is sensitive to the detection of the most prevalent and high-risk HPV with additional information about the integration status, where episomal (non-integrated) forms of HPV are less risky than the forms integrated into genomic DNA. This is valuable in obtaining in-depth information on the process of carcinogenesis and to precisely assess the risk of progression to cancer. The method is based on polymerase chain reaction, it is simple, quick and reliable.
A partner with manufacturing ability according to technology documentation, support for further technology related research and development and the ability to place the technology on global markets based on a joint-venture agreement, licence agreement or manufacturing agreement is sought.
Advantages and Innovations:
The main benefit of the technology over the existing diagnostic systems is differentiation of the free episomal versus integrated form of the human papilloma virus (HPV). HPV integration has been associated with disease progression and the technology is capable of absolute quantification of HPV loads in the sample with high sensitivity. Control gene detection serves as an internal control of the amplification and/or presence of DNA added to PCR reaction. The technology is currently able to detect 16,18,31 and 56 genotypes and can be further adapted for other genotypes.
Stage of Development:
Field tested/evaluated
IPs:
Secret know-how
CommeR Statunts Regarding IPR Status:
Trade secret, more detail under the non-discloser agreement (CDA)

Partner sought

Type and Role of Partner Sought:
Manufacturing ability according to technology documentation, support for further technology related research and development and the ability to place the technology on global markets. The co-operation will be based on a joint-venture agreement, licence agreement or manufacturing agreement.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
Czech
English

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001018 Virus, virología / antibióticos / bacteriología